Both retrospective [10] and prospective [11] studies aiming to assess the predictive utility of ERCC1 status for platinum-based chemotherapy in NSCLC have revealed improved clinical outcomes by integrating patient’s ERCC1 status in developing individualized therapy [12, 13]. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.